A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

Starting soon · Phase 3 · Has a placebo group

Conditions studied: Hypercholesterolaemia

In brief

The purpose of this study is to evaluate the effect on low-density lipoprotein-cholesterol (LDL-C) and the safety and tolerability of a fixed dose combination (FDC) of laroprovstat/rosuvastatin versus rosuvastatin alone in patients with hypercholesterolaemia with either a history of a clinical atherosclerotic cardiovascular disease (ASCVD) event or at increased risk for a first clinical ASCVD event.

Key facts

Study ID

NCT07619118

Run by

AstraZeneca

People needed

200

Starts

2026-09-15

Expected to finish

2027-05-28

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be ≥ 18 years of age
• Participants must be on a stable dose of all background LLTs
• The stable statin dose should be judged as their maximally tolerated dose
• Participants should have either history of a clinical ASCVD event or be at increased risk for a first clinical ASCVD event

You may not qualify if…

• Asian origin
• Uncontrolled severe hypertension
• Uncontrolled T2DM
• Inadequately treated hypothyroidism

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.